Support for Your Plasma Protein Therapeutics
Our plasma protein therapeutic platforms fulfill a critical role ideal for niche development and manufacturing programs, such as those for rare and orphan diseases and venom antitoxins. Working with customers to provide plasma protein-derived therapeutics is where Emergent CDMO excels.
Emergent has expertise with regulatory-approved human and equine plasma products generated for targeted therapies. For decades, our hyperimmune specialty plasma antibody manufacturing platform has been used to create multiple drugs up to a scale of 1000L.
- Human Platform – Purified gamma globulin (IgG) containing polyclonal antibodies to specific antigens obtained from human plasma.
- Equine Platform – Purified immunoglobulin fragments derived from polyclonal antibodies to specific antigens obtained from equine plasma.
